Table 2. HIV-1 Plasma RNA and Cell-Associated DNA During Analytical Treatment Interruption.
| Post-ATI Sample Day | Plasma RNA (copies/ml) | Whole Blood or PBMC DNA |
|---|---|---|
| Patient A | ||
| 7, 25, 35, 49, 70 | DNA not detected on all days (blood)a | |
| 14, 25, 28, 35, 42, 49, 56, 70 | <20b | |
| 84 | 904 | DNA detected (blood) |
| 88c | 127843 | 13 copies/106 PBMCs |
| 105 | 3225526 | |
| 112 | 1255960 | |
| 117 | 4173922 | 676 copies/106 PBMCs |
| 124 | 345634 | |
| 126 | 77504 | |
| 130 | 66977 | |
| 133 | 73369 | |
| 138 | 23222 | |
| 154 | 4344 | |
| 170 | 1388 | |
| 168 | 1114 | |
| 192 | 646 | 105 copies/106 PBMCs |
| 203 | 1028 | |
| 226 | (20202) d | |
| 241 | 183 | |
| 248 | 75 | |
| 252 | 93 | |
| 266 | 81 | |
| 280 | 110 | |
| 302 | 1420 | |
| 314 | 255 | |
| 319 | 21 | |
| Patient B | ||
| 14, 30, 64, 94, 122, 141, 156, 176, 199 | DNA not detected on all days (blood)a | |
| 38 | <0.4e | <0.5 copies/106 PBMCsb |
| 129 | <0.4e | <0.2 copies/106 PBMCsb |
| 7, 14, 22, 30, 38, 46, 56, 64, 78, 94, 106, 122, 129, 141, 149, 156, 164, 176, 185, 199, 211 | <20b | |
| 225 | 1900000 | |
| 233 | 174577 | |
| 238f | 32185 | 1100 copies/106 PBMCs |
| 247 | 10269 | |
| 255 | 3160 | |
| 266 | 385 | |
| 278 | 171 | 318 copies/106 PBMCs |
| 290 | 42 | |
| 304 | 44 | |
| 326 | <20 (detected) | |
| 350 | <20 (detected) | |
Abbreviations: ATI, analytical treatment interruption; PBMC, peripheral blood mononuclear cell
a
Clinical laboratory validated detection threshold was 250 HIV-1 DNA copies/ml of whole blood, but the assay may detect fewer DNA copies
b
No HIV-1 detected
c
RNA detected in cerebral spinal fluid, but <20 copies/ml
d
Positive value may have been due to sample mix-up at clinical laboratory, unable to verify sample was from day 226 and not an earlier time point
e
No RNA detected by single-copy assay
f
Cerebral spinal fluid viral load = 269 copies/ml